Visible Genomics

Executive Summary

Visible Genomics is a US-based diagnostics company founded in 2019 and headquartered in Cambridge, Massachusetts, focused on developing genetic testing products for Age-Related Macular Degeneration (AMD), a leading cause of vision loss. The company’s platform integrates DNA analysis with patient health factors to deliver personalized risk assessments for AMD onset and progression. By addressing the growing need for early detection and tailored management of AMD, Visible Genomics aims to empower clinicians and patients with actionable insights that can delay vision loss and improve outcomes. The company operates in the rapidly expanding precision diagnostics market, leveraging advances in genomics and AI to differentiate its offerings. Despite the compelling value proposition, Visible Genomics operates in a competitive landscape with established players and emerging startups. The company’s stage and funding status remain undisclosed, suggesting it may be in early commercial or development phase. If successful, Visible Genomics could capture significant share in the AMD diagnostics segment, which is fueled by an aging population and increasing awareness of genetic risk factors. However, the lack of disclosed milestones and financial data limits visibility into its near-term trajectory. The company’s ability to secure partnerships, generate clinical evidence, and achieve regulatory clarity will be critical for growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation AMD risk test incorporating multi-omics biomarkers60% success
• Q4 2026Strategic partnership with a major retinal specialist network or ophthalmic clinic chain50% success
• Q2 2026Publication of a validation study demonstrating improved predictive accuracy over standard models70% success